Skip to main content
Patient ID and Site ID

Find the right patients and the right sites, faster

A community-weighted research network and oncology-specific AI pre-screening work together, so teams spend less time guessing which sites and patients are a fit, and more time activating them.

A network of 225+ sites feeds OncoLens AI feasibility, checked by human review, and the matched sites confirm interest. At those sites, OncoLens AI pre-screening, again with human review, identifies the patients.

How OncoLens helps

Four ways teams stop guessing and start activating.

Network

Access to the OncoLens Research Network

  • Reach that goes where most oncology patients are treated
  • 225+ cancer center locations, 90% community-based
  • Spanning Phase 1 to 4 studies, CAR-T, RLT and specialized therapies
Site ID

Feasibility-based connections, not a directory

  • Outreach goes where there is a real chance of enrolling
  • OncoLens matches centers and PIs on demonstrated fit for your protocol
  • OncoLens makes the introduction directly
Patient ID

Oncology-focused AI pre-screening

  • Built for the complexity of oncology, not adapted to it
  • OncoLens reviews patient data against trial eligibility criteria
  • A human in the loop confirms every match before contact
Reporting

Analytics reported back to you

  • Turnkey dashboards and personalized alerts
  • Patients deemed medically eligible
  • Declines, and the reasons for decline

What comes back to you

Every match is confirmed by a clinical team before it reaches you. On each trial you get who is medically eligible, whether they were randomized or declined, and the reason behind each.

EVERY ONE SCREENED BY A CLINICAL TEAM

Medically eligible

Randomized
Declined With the reason for each
  • Prior therapy
  • Disease stage
  • Performance status
  • Biomarker status
  • Social drivers of health
  • Timeliness
County-level map showing where patients under care in the OncoLens network are concentrated across the United States, with Alaska and Hawaii shown as insets
Where patients under care are concentrated
225+U.S.-based cancer center locations
6,000,000+patients under care
90%community-based
88%AI-extracted insights

Frequently asked questions

How does OncoLens identify oncology clinical trial sites?

Through the OncoLens Research Network: 225+ cancer center locations, roughly 90% community-based, spanning Phase 1 to 4 studies, CAR-T, RLT and specialized therapies, with feasibility-based connections and direct introductions to centers and principal investigators.

What does “feasibility-based” mean in site identification?

Centers and PIs are matched based on demonstrated fit for a specific protocol and patient population, rather than surfaced from a generic directory, so outreach goes to sites with a real chance of activating and enrolling.

How does the patient pre-screening work?

Oncology-focused AI reviews patient data against trial eligibility criteria and surfaces likely candidates through turnkey dashboards and personalized alerts, with a human in the loop confirming every match before contact.

What analytics come back from the pre-screening process?

Reporting on key trial stats, including the number of patients deemed medically eligible, the number declined, and the reasons for decline, giving visibility into where a trial gains or loses candidates.

Is this only useful for large academic medical centers?

No. Because the network is roughly 90% community-based, site and patient identification reaches populations and centers that an academic-only approach would miss.

Get in touch

Find your next patient or site

Bring your protocol. OncoLens will show you which centers fit it, which patients screen in, and what the analytics say about both.